Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor Puzanov

Showing results (141-150 of 208) with videos related to

Pageof 21
Sort By:
JAMA Oncology|December 1, 2017
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET StudyEli L Diamond, Vivek Subbiah, A Craig Lockhart, et al.
Journal of Translational Medicine|July 23, 2018
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, et al.
Cancer|August 18, 2016
The efficacy of anti-PD-1 agents in acral and mucosal melanomaAlexander N Shoushtari, Rodrigo R Munhoz, Deborah Kuk, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2024
Differences in systemic immune parameters in individuals with lung cancer according to raceMitchell S von Itzstein, Jialiang Liu, Hong Mu-Mosley, et al.
Kidney Cancer Journal : Official Journal of the Kidney Cancer Association|November 12, 2021
Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trialSusan Halabi, Qian Yang, Andrea Carmack, et al.
JTO Clinical and Research Reports|December 2, 2024
Racial Differences in Systemic Immune Parameters in Individuals With Lung CancerMitchell S von Itzstein, Jialiang Liu, Hong Mu-Mosley, et al.
Cells|December 17, 2024
Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to ImmunotherapyIslam Eljilany, Sam Coleman, Aik Choon Tan, et al.
European Urology|May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) TrialPrimo N Lara, Catherine Tangen, Elisabeth I Heath, et al.
Lancet (London, England)|July 31, 2023
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trialChristopher W Ryan, Catherine M Tangen, Elisabeth I Heath, et al.
Journal for Immunotherapy of Cancer|July 28, 2022
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancerAnn W Silk, Christopher A Barker, Shailender Bhatia, et al.
Pageof 21

Showing results (141-150 of 208) with videos related to

Sort By:
Pageof 21
JAMA Oncology|December 1, 2017
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET StudyEli L Diamond, Vivek Subbiah, A Craig Lockhart, et al.
Journal of Translational Medicine|July 23, 2018
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, et al.
Cancer|August 18, 2016
The efficacy of anti-PD-1 agents in acral and mucosal melanomaAlexander N Shoushtari, Rodrigo R Munhoz, Deborah Kuk, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2024
Differences in systemic immune parameters in individuals with lung cancer according to raceMitchell S von Itzstein, Jialiang Liu, Hong Mu-Mosley, et al.
Kidney Cancer Journal : Official Journal of the Kidney Cancer Association|November 12, 2021
Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trialSusan Halabi, Qian Yang, Andrea Carmack, et al.
JTO Clinical and Research Reports|December 2, 2024
Racial Differences in Systemic Immune Parameters in Individuals With Lung CancerMitchell S von Itzstein, Jialiang Liu, Hong Mu-Mosley, et al.
Cells|December 17, 2024
Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to ImmunotherapyIslam Eljilany, Sam Coleman, Aik Choon Tan, et al.
European Urology|May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) TrialPrimo N Lara, Catherine Tangen, Elisabeth I Heath, et al.
Lancet (London, England)|July 31, 2023
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trialChristopher W Ryan, Catherine M Tangen, Elisabeth I Heath, et al.
Journal for Immunotherapy of Cancer|July 28, 2022
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancerAnn W Silk, Christopher A Barker, Shailender Bhatia, et al.
Pageof 21